Navigation Links
Ataluren Phase 2 Data in Nonsense Mutation Cystic Fibrosis Published in the European Respiratory Journal
Date:7/1/2011

mutations are the cause of CF in about 10% of patients. Ataluren, a protein restoration therapy, is designed to overcome the nonsense mutation and enable the production of a full-length, functional CFTR protein. A genetic test can determine if a patient's disease is caused by a nonsense mutation.

"The results from this study strongly support the conduct of longer term studies to evaluate the clinical benefit of ataluren for patients with nonsense mutation cystic fibrosis," said Robert Spiegel, M.D., Chief Medical Officer of PTC Therapeutics. "A 48-week placebo-controlled Phase 3 study of ataluren in nonsense mutation cystic fibrosis is fully enrolled and we look forward to the availability of data in the first half of 2012."

ABOUT THE PHASE 2 EXTENSION STUDY

The Phase 2 clinical trial (Study 005e) was an extension of a previously conducted short-term open-label Phase 2a proof-of-concept trial (Study 005) of ataluren in adults with nmCF. Study 005e enrolled 19 patients, aged 19 years and older, who received one of two ataluren doses three times per day (morning, midday and evening) for 12 weeks (84 days). On-treatment clinic visits were conducted every 28 days, with an additional follow-up clinic visit at Day 112. The study was conducted at the Hadassah Hebrew University Hospital in Jerusalem, Israel and sponsored by PTC Therapeutics.

The study's primary endpoint was CFTR chloride channel activity as assessed by nasal transepithelial potential difference (NPD). A response was predefined as an improvement of at least -5.0 mV from baseline in total chloride transport. The results showed that ataluren induced statistically significant improvements in chloride channel activity at each dose level and for all patients combined. The aggregate mean change in total chloride transport for all patients was -5.4 mV (p<0.001).

Secondary endpoints of lung function included evaluations of forced expiratory volume in 1 second (FEV1) and
'/>"/>

SOURCE PTC Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. PTC Therapeutics Completes Enrollment of Phase 3 Trial of Ataluren in Patients with Cystic Fibrosis
2. PTC Therapeutics Announces Additional Study of Ataluren in Patients with Advanced Nonsense Mutation Duchenne/Becker Muscular Dystrophy
3. Endo Announces Topline Results From Phase 2 Study of Axomadol in Chronic Low Back Pain
4. Phase III Study Shows Once-Daily NVA237 is Superior to Placebo and Similar to Tiotropium in Improving Lung Function in COPD
5. DNA Medicine Institute Awarded Two Phase III SBIR NASA Contracts for Its rHEALTH Sensor
6. Phase I of the Swedish/Issaquah Medical Center Campus to Open in July
7. The Lancet Publishes Data from Protege, MacroGenics Phase 3 Clinical Study of Teplizumab in Type 1 Diabetes Patients
8. Morphotek®, Inc. Announces Initiation of Farletuzumab Phase II Study in First-Line Treatment of Non-Small Cell Lung Cancer
9. Palatin Technologies, Inc. Initiates Enrollment in Phase 2b Trial With Bremelanotide in Women With Female Sexual Dysfunction
10. Cardium Announces Plans to Acquire Transdel Pharmaceuticals Phase 3 Topical Analgesic and Cosmeceutical Business Assets
11. Glycotex, Inc. Releases Final Phase II Clinical Trials Results in the Clinicaltrials.gov Database and Announces the Results of the Mechanism of Action Study for its Product Candidate GLYC-101
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... 29, 2014 Research and Markets ... Cancer Therapeutics Market & Pipeline Insight 2014" report ... developed to prevent and eradicate the prevalence of cancer ... are confined to low specificity, safety and large number ... for a better solution. It has been discovered that ...
(Date:8/29/2014)... SPRING, Md. , Aug. 29, 2014  United ... that the U.S. District Court for the District of ... its favor in the company,s case against Sandoz, Inc. ... Judge Peter Sheridan ruled that U.S. Patent ... Inc., and enjoined Sandoz from marketing its generic product ...
(Date:8/29/2014)... Aug. 29, 2014 /PRNewswire-iReach/ -- ChemImage will present a ... and New Zealand Forensic Science Society,s 22 nd ... Adelaide, Australia .  Forensic Scientists ... advancements that hyperspectral imaging can bring to examination ... , Director of Product Development at ChemImage, will ...
Breaking Medicine Technology:Global Peptide Cancer Therapeutics Market & Pipeline Insight 2014 2District Court Decision Received In Remodulin Patent Case 2ChemImage to Discuss Hyperspectral Imaging for Forensic Investigation at the ANZFSS 22nd International Symposium on the Forensic Sciences 2ChemImage to Discuss Hyperspectral Imaging for Forensic Investigation at the ANZFSS 22nd International Symposium on the Forensic Sciences 3
(Date:8/30/2014)... Atlanta, GA (PRWEB) August 30, 2014 ... US Open Challenge and K.Warrior Search on November 8th, ... Over 20 years, these events have introduced many notorious ... such as Strike-Force, IWF and the UFC. , ... seen numerous fighters leave its doors armed with the ...
(Date:8/30/2014)... 30 August 2014: The first multidisciplinary recommendations on ... coronary syndromes (ACS) are published today in ... written jointly by the European Heart Rhythm Association ... the European Association of Percutaneous Cardiovascular Interventions (EAPCI), ... Gorenek (Turkey), chairperson of the task force, said: ...
(Date:8/30/2014)... Saturday 30 August 2014: The first recommendations on ... pulmonary embolism are published today in new ESC ... by Professor Stavros V. Konstantinides (Germany/Greece) and Professor ... on the diagnosis and management of acute pulmonary ... Journal (1) and on the ESC Website. , ...
(Date:8/29/2014)... Daily Gossip writes in its review that this is ... This method promises to teach readers how to eliminate the ... alternative sources for the production of energy. , Some ... solar power. , The Home Made Energy review indicates ... So, this is an online guide that will teach its ...
(Date:8/29/2014)... (PRWEB) August 30, 2014 Cancer ... loved ones and caretakers. Author Eddie M. Leung knows the ... cholangiocarcinoma or bile duct cancer, a very rare and ... That Changed My Life” (published by Xlibris), he shares a ... importantly, he imparts a survivor’s testimony that this disease can ...
Breaking Medicine News(10 mins):Health News:KSF Presents US Open Challenge-K. Warrior Search, Seeking Inspirational Warrior Fighters Like Cung Le 2Health News:KSF Presents US Open Challenge-K. Warrior Search, Seeking Inspirational Warrior Fighters Like Cung Le 3Health News:KSF Presents US Open Challenge-K. Warrior Search, Seeking Inspirational Warrior Fighters Like Cung Le 4Health News:First multidisciplinary recommendations on management of arrhythmias in ACS patients 2Health News:First recommendations on all new oral anticoagulants in pulmonary embolism published 2Health News:Home Made Energy Review Exposes Simple Method to Access Alternative Energy Sources 2Health News:Eddie M. Leung Shares His Testimony As a Survivor of Cancer 2Health News:Eddie M. Leung Shares His Testimony As a Survivor of Cancer 3
... may not be at,the top of your list of fun ... makes having any kind of fun a lot harder in ... your fiber intake, while enjoying the,benefits of regularity., Listen ... http://media.medialink.com/WebNR.aspx?story=35262 ., Registered journalists can access video, audio, text, ...
... Ind., June 19 Zimmer Holdings, Inc.,(NYSE: ... that it will partner with AmeriCares,one of ... donations, to support emergency response and ongoing ... at $1 million to,three of AmeriCares, primary ...
... a major international clinical trial coordinated by the Montreal ... England Journal of Medicine . The Atrial Fibrillation and ... project involving patients with heart failure and atrial fibrillation. ... the population and associated atrial fibrillation (a very common ...
... for diarrhea worldwide, study says , , THURSDAY, June 19 (HealthDay ... may help dysentery-causing amoeba evade the immune system. , ... fight dysentery, a form of diarrhea that affects about 500 ... threat in many regions. , "This is the first ...
... June 19 NightHawk,Radiology Holdings, Inc. (Nasdaq: NHWK ... and hospitals throughout the United States,today announced the final ... at 5:00 p.m. Eastern Time on Friday, June 13, ... depositary for the tender offer, an,aggregate of 2,240,883 shares ...
... June 19 Minneapolis-based Courage Center,is pleased to announce ... 2008,Eleven Who Care Agency of Distinction., Over the ... has,recognized the outstanding efforts of 264 (275 including 2008) ... amazing. Since the,awards began, 12 Courage Center volunteers (including ...
Cached Medicine News:Health News:Zimmer Holdings to Partner with AmeriCares for Global Product Donation Program 2Health News:Zimmer Holdings to Partner with AmeriCares for Global Product Donation Program 3Health News:The Montreal Heart Institute presents findings on congestive heart failure and atrial fibrillation 2Health News:The Montreal Heart Institute presents findings on congestive heart failure and atrial fibrillation 3Health News:Scientists ID Enzyme That Allows Dysentery Amoeba to Hide 2Health News:NightHawk Radiology Holdings, Inc. Announces Final Results of Tender Offer; NightHawk Purchases 2,240,883 Shares of Its Common Stock at $8.05 per Share 2Health News:Courage Center Honored With KARE TV's 2008 Eleven Who Care Agency of Distinction 2
... with brass and aluminum body., ... suffix S to model number. Example: ... suffix C to model number. Example: ... Power Take-Off, add PT to model ...
... FM Series Oxygen Flowmeters with Power ... security chain, add suffix S to ... Canadian Color-Code, add suffix C to ... Double Flowmeters with Power Take-Off, add ...
... proficiency testing solutions with outstanding customer service ... is one of the largest proficiency testing ... laboratories enrolled. Here are just some of ... Paperless Proficiency Testing, Free CME/CMLE Credits ...
... a new functional test which exhibits 100% ... C Resistance caused by the Factor V ... commercially available methods, Pefakit APC-R FVL shows ... Lupus Anticoagulants, Elevated FVIII levels, Heparins or ...
Medicine Products: